Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity

Piaopiao Li(Stone Mountain Technologies (United States)), Hui Shao(Tulane University), Rodolfo J. Galindo(University of Miami), Jithin Sam Varghese(Emory University), Mohammed K. Ali(Emory University), Francisco J. Pasquel(Emory University), Megha Shah(Emory University)
JAMA Network Open
October 31, 2025
10.1001/jamanetworkopen.2025.40890
Cited by 29

Related Papers

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
|The Lancet|2012|9k
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
|The Lancet|2012|8.4k
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
|The Lancet|2016|4.4k
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
|The Lancet|2011|3.6k
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
|The Lancet|2015|2.8k